BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 10741727)

  • 1. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
    Middlemas DS; Stewart CF; Kirstein MN; Poquette C; Friedman HS; Houghton PJ; Brent TP
    Clin Cancer Res; 2000 Mar; 6(3):998-1007. PubMed ID: 10741727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
    Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Kirstein MN; Poquette CA; Tan M; Friedman HS; Brent TP
    Clin Cancer Res; 2000 Oct; 6(10):4110-8. PubMed ID: 11051264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
    Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
    Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
    J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
    Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
    Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
    Querfeld C; Rosen ST; Guitart J; Rademaker A; Pezen DS; Dolan ME; Baron J; Yarosh DB; Foss F; Kuzel TM
    Clin Cancer Res; 2011 Sep; 17(17):5748-54. PubMed ID: 21747120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
    von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
    Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy.
    Ma S; Egyházi S; Ringborg U; Hansson J
    Oncol Rep; 2002; 9(5):1015-9. PubMed ID: 12168066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents.
    Srivenugopal KS; Shou J; Mullapudi SR; Lang FF; Rao JS; Ali-Osman F
    Clin Cancer Res; 2001 May; 7(5):1398-409. PubMed ID: 11350911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
    Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
    Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest.
    Sato K; Kitajima Y; Kohya N; Miyoshi A; Koga Y; Miyazaki K
    Int J Oncol; 2005 Jun; 26(6):1653-61. PubMed ID: 15870882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifaceted resistance of gliomas to temozolomide.
    Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
    Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
    Aghi M; Rabkin S; Martuza RL
    J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
    Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
    Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of o6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea(ACNU) in gallbladder carcinoma cells.
    Sato K; Kitajima Y; Koga Y; Miyazaki K
    Anticancer Res; 2005; 25(6B):4021-8. PubMed ID: 16309194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual repair modulation reverses Temozolomide resistance in vitro.
    Barvaux VA; Ranson M; Brown R; McElhinney RS; McMurry TB; Margison GP
    Mol Cancer Ther; 2004 Feb; 3(2):123-7. PubMed ID: 14985452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
    Boeckmann L; Schirmer M; Rosenberger A; Struever D; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Schoen MP; Brockmoeller J; Emmert S
    Pharmacogenet Genomics; 2009 Oct; 19(10):760-9. PubMed ID: 19741564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
    Ma J; Murphy M; O'Dwyer PJ; Berman E; Reed K; Gallo JM
    Biochem Pharmacol; 2002 Apr; 63(7):1219-28. PubMed ID: 11960598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide.
    Ezaki T; Sasaki H; Hirose Y; Miwa T; Yoshida K; Kawase T
    Mol Med Rep; 2011; 4(6):1101-5. PubMed ID: 21874248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.